Compare Abeona Therapeutics Inc (ABEO) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Williams-Sonoma, Inc. — how do they compare? Abeona Therapeutics Inc trades at $7.37 (market cap $421.19M), while Williams-Sonoma, Inc. trades at $246.22 (market cap $29.51B). The key difference: Williams-Sonoma, Inc. is far larger — about 70.1× Abeona Therapeutics Inc's market cap, and Williams-Sonoma, Inc. pays a 1.21% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | WSM | |
|---|---|---|
Market Cap | $421.19M | $29.51B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.45 | $251.81 |
52-Week Low | $4.17 | $168.64 |
Enterprise Value | $276.10M | $30.35B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.40, down 0.67% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 2026 results with revenue growth and beat EPS estimates for three consecutive quarters. Recent news includes CMS granting NTAP status for ZEVASKYN and expansion of its treatment center network, indicating positive commercial momentum.
Outlook is supported by analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high P/S ratio, negative operating cash flow, and a shareholder investigation. The stock's valuation remains attractive on P/E and EV/EBITDA bases, though execution on revenue growth is critical for sustained upside.
Williams-Sonoma (WSM) trades at $246.14, down 1.87% on the day, amid a generally bullish technical outlook. The stock shows strong profitability with a net income margin of 13.81% and has beaten earnings estimates for three consecutive quarters. Recent news highlights its digital-first transformation and competitive strength in home furnishings.
The outlook is supported by solid fundamentals and positive earnings momentum, but high valuation ratios and overbought RSI levels pose near-term risks. Analyst consensus is mixed, with a moderate buy rating but a price target below the current price, suggesting cautious optimism amid execution and consumer spending concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
